WO2023073469 - STABLE LYOPHILIZED FORMULATION OF AN ANTI-α4ß7 ANTIBODY
National phase entry:
Publication Number
WO/2023/073469
Publication Date
04.05.2023
International Application No.
PCT/IB2022/059777
International Filing Date
12.10.2022
Title **
[English]
STABLE LYOPHILIZED FORMULATION OF AN ANTI-α4ß7 ANTIBODY
[French]
FORMULATION LYOPHILISÉE STABLE D'UN ANTICORPS ANTI-α4Β7
Applicants **
INTAS PHARMACEUTICALS LTD.
Corporate House, Near Sola Bridge,
S. G. Highway, Thaltej, Ahmedabad - 380054,
Gujarat, India.
Ahmedabad 380054, IN
Inventors
INGARODIYA, Kinjal
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad-382213.
Gujarat, India.
Ahmedabad 382213, IN
JANGLE, Rahul
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad-382213.
Gujarat, India.
Ahmedabad 382213, IN
NAIR, Pravin A.
Intas Pharmaceuticals Limited – Biopharma Division,
Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad-382213.
Gujarat, India.
Ahmedabad 382213, IN
Priority Data
202121049583
29.10.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 968 | |
| EPO | Filing, Examination | 6428 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 11275 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides stable lyophilized formulation of anti-α4ß7 antibody comprising buffer, sugar, bulking agent, viscosity reducer, antioxidant and surfactant.[French]
L'invention concerne une formulation lyophilisée stable d'anticorps anti-α4β7 comprenant un tampon, un sucre, un agent gonflant, un réducteur de viscosité, un antioxydant et un tensioactif.